KI-Hyperactivity Model and Dopamine Endpoint Suite for ADHD Drug Screening

A preclinical screening service anchored on the Cdh2 H150Y knock-in mouse — which carries an exact human ADHD mutation — packaged with standardized behavioral, synaptic, and dopamine assays and methylphenidate as a built-in positive control. New evidence extends the package with a second model line built from GWAS-implicated GABA risk genes plus excitatory/inhibitory-balance endpoints, aimed at programs targeting the roughly one-third of patients who fail stimulants. Because ADHD is mostly polygenic and open-field locomotion is confounded by anxiety and genetic background, the service is positioned as a multi-line, mechanistic screen rather than a general model of ADHD.